Literature DB >> 8978680

Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation.

W S Alexander1, A B Maurer, U Novak, M Harrison-Smith.   

Abstract

Interaction of thrombopoietin (TPO) with its receptor, c-Mpl, triggers cell growth and differentiation responses controlling primitive haemopoietic cell production and megakaryocytopoiesis. To examine the important receptor domains and signal transduction pathways involved in these cellular responses, c-Mpl cytoplasmic domain truncation and tyrosine substitution mutants were generated. In the myelomonocytic leukaemia cell lines WEHI3B-D+ and M1, ectopic expression of the wild-type c-Mpl receptor induced TPO-dependent cellular differentiation characterized by increased cell migration through agar and acquisition of the morphology and molecular markers of macrophages. Consistent with the concept that proliferative and differentiation signals emanate from distinct receptor domains, the C-terminal 33 amino acids of c-Mpl were dispensable for a proliferative response in Ba/F3 cells but proved critical for WEHI3B-D+ and M1 differentiation. Finer mapping revealed that substitution of Tyr599 by phenylalanine within this c-Mpl domain was sufficient to abolish the normal differentiation response. Moreover, in contrast to the normal c-Mpl receptor, this same mplY599F mutant was also incapable of stimulating TPO-dependent Shc phosphorylation, the association of Shc with Grb2 or c-Mpl and of inducing c-fos expression. Thus activation of components of the Ras signalling cascade, initiated by interaction of Shc with c-Mpl Tyr599, may play a decisive role in specific differentiation signals emanating from the c-Mpl receptor.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8978680      PMCID: PMC452478     

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  54 in total

1.  cMpl ligand is a humoral regulator of megakaryocytopoiesis.

Authors:  F Wendling; E Maraskovsky; N Debili; C Florindo; M Teepe; M Titeux; N Methia; J Breton-Gorius; D Cosman; W Vainchenker
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

2.  Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation.

Authors:  T Miyazaki; Z J Liu; A Kawahara; Y Minami; K Yamada; Y Tsujimoto; E L Barsoumian; R M Permutter; T Taniguchi
Journal:  Cell       Date:  1995-04-21       Impact factor: 41.582

3.  The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl.

Authors:  J G Drachman; J D Griffin; K Kaushansky
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

4.  Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro.

Authors:  V C Broudy; N L Lin; K Kaushansky
Journal:  Blood       Date:  1995-04-01       Impact factor: 22.113

5.  Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets.

Authors:  Y Miyakawa; A Oda; B J Druker; T Kato; H Miyazaki; M Handa; Y Ikeda
Journal:  Blood       Date:  1995-07-01       Impact factor: 22.113

6.  Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates.

Authors:  A M Farese; P Hunt; T Boone; T J MacVittie
Journal:  Blood       Date:  1995-07-01       Impact factor: 22.113

7.  Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation.

Authors:  A L Gurney; S C Wong; W J Henzel; F J de Sauvage
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

8.  Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2.

Authors:  P J Tortolani; J A Johnston; C M Bacon; D W McVicar; A Shimosaka; D Linnekin; D L Longo; J J O'Shea
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

9.  In vitro megakaryocytopoietic and thrombopoietic activity of c-mpl ligand (TPO) on purified murine hematopoietic stem cells.

Authors:  F C Zeigler; F de Sauvage; H R Widmer; G A Keller; C Donahue; R D Schreiber; B Malloy; P Hass; D Eaton; W Matthews
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

10.  Thrombopoietin activates a STAT5-like factor in hematopoietic cells.

Authors:  C Pallard; F Gouilleux; L Bénit; L Cocault; M Souyri; D Levy; B Groner; S Gisselbrecht; I Dusanter-Fourt
Journal:  EMBO J       Date:  1995-06-15       Impact factor: 11.598

View more
  19 in total

1.  Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.

Authors:  M C Rouyez; C Boucheron; S Gisselbrecht; I Dusanter-Fourt; F Porteu
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

2.  C-Mpl Is Expressed on Osteoblasts and Osteoclasts and Is Important in Regulating Skeletal Homeostasis.

Authors:  Tomas E Meijome; Jenna T B Ekwealor; R Adam Hooker; Ying-Hua Cheng; Wendy A Ciovacco; Sanjeev M Balamohan; Trishya L Srinivasan; Brahmananda R Chitteti; Pierre P Eleniste; Mark C Horowitz; Edward F Srour; Angela Bruzzaniti; Robyn K Fuchs; Melissa A Kacena
Journal:  J Cell Biochem       Date:  2015-10-06       Impact factor: 4.429

3.  Towards predictive models of stem cell fate.

Authors:  Sowmya Viswanathan; Peter W Zandstra
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

4.  Permissive role of thrombopoietin and granulocyte colony-stimulating factor receptors in hematopoietic cell fate decisions in vivo.

Authors:  R Stoffel; S Ziegler; N Ghilardi; B Ledermann; F J de Sauvage; R C Skoda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

5.  Orientation-specific signalling by thrombopoietin receptor dimers.

Authors:  Judith Staerk; Jean-Philippe Defour; Christian Pecquet; Emilie Leroy; Hélène Antoine-Poirel; Ian Brett; Miki Itaya; Steven O Smith; William Vainchenker; Stefan N Constantinescu
Journal:  EMBO J       Date:  2011-09-02       Impact factor: 11.598

Review 6.  Megakaryopoiesis.

Authors:  Amy E Geddis
Journal:  Semin Hematol       Date:  2010-07       Impact factor: 3.851

Review 7.  Cytokine receptor splice variants in hematologic diseases.

Authors:  Borwyn Wang; Hrishikesh Mehta
Journal:  Cytokine       Date:  2019-12-06       Impact factor: 3.861

Review 8.  Molecular control of megakaryopoiesis and thrombopoiesis.

Authors:  Itaru Matsumura; Yuzuru Kanakura
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

9.  A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.

Authors:  Xiaoli Wang; David Haylock; Cing Siang Hu; Wioleta Kowalczyk; Tianbo Jiang; Jiajing Qiu; Goar Mosoyan; Wu He; Netonia Marshall; John Mascarenhas; Anna Tarasova; Joshua Brody; David Winkler; Ronald Hoffman
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

10.  Involvement of prolonged ras activation in thrombopoietin-induced megakaryocytic differentiation of a human factor-dependent hematopoietic cell line.

Authors:  I Matsumura; K Nakajima; H Wakao; S Hattori; K Hashimoto; H Sugahara; T Kato; H Miyazaki; T Hirano; Y Kanakura
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.